Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

Alba A. Brandes; E. Franceschi; Thierry Gorlia; Wolfgang Wick; A. H. Jacobs; B. G. Baumert; Martin J. van den Bent; C.M. Weller; Roger Stupp

doi:10.1016/j.ejca.2011.10.027

Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

Alba A. Brandes^*, E. Franceschi, Thierry Gorlia, Wolfgang Wick, A. H. Jacobs, B. G. Baumert, Martin J. van den Bent, C.M. Weller, Roger Stupp

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	896-903
Journal	European Journal of Cancer
Volume	48
Issue number	6
DOIs	https://doi.org/10.1016/j.ejca.2011.10.027
Publication status	Published - Apr 2012

Keywords

Recurrent glioblastoma
End-points
Overall survival
Progression-free survival
Overall survival rates

Access to Document

10.1016/j.ejca.2011.10.027

Cite this

Brandes, A. A., Franceschi, E., Gorlia, T., Wick, W., Jacobs, A. H., Baumert, B. G., van den Bent, M. J., Weller, C. M., & Stupp, R. (2012). Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. European Journal of Cancer, 48(6), 896-903. https://doi.org/10.1016/j.ejca.2011.10.027

Brandes, Alba A. ; Franceschi, E. ; Gorlia, Thierry ; Wick, Wolfgang ; Jacobs, A. H. ; Baumert, B. G. ; van den Bent, Martin J. ; Weller, C.M. ; Stupp, Roger. / Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. In: European Journal of Cancer. 2012 ; Vol. 48, No. 6. pp. 896-903.

@article{af283601bc9b4ee2a88b46d080c56b43,

title = "Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma",

keywords = "Recurrent glioblastoma, End-points, Overall survival, Progression-free survival, Overall survival rates",

author = "Brandes, {Alba A.} and E. Franceschi and Thierry Gorlia and Wolfgang Wick and Jacobs, {A. H.} and Baumert, {B. G.} and {van den Bent}, {Martin J.} and C.M. Weller and Roger Stupp",

year = "2012",

month = apr,

doi = "10.1016/j.ejca.2011.10.027",

language = "English",

volume = "48",

pages = "896--903",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

number = "6",

}

Brandes, AA, Franceschi, E, Gorlia, T, Wick, W, Jacobs, AH, Baumert, BG, van den Bent, MJ, Weller, CM & Stupp, R 2012, 'Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma', European Journal of Cancer, vol. 48, no. 6, pp. 896-903. https://doi.org/10.1016/j.ejca.2011.10.027

Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma. / Brandes, Alba A.; Franceschi, E.; Gorlia, Thierry; Wick, Wolfgang; Jacobs, A. H.; Baumert, B. G.; van den Bent, Martin J.; Weller, C.M.; Stupp, Roger.

In: European Journal of Cancer, Vol. 48, No. 6, 04.2012, p. 896-903.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

AU - Brandes, Alba A.

AU - Franceschi, E.

AU - Gorlia, Thierry

AU - Wick, Wolfgang

AU - Jacobs, A. H.

AU - Baumert, B. G.

AU - van den Bent, Martin J.

AU - Weller, C.M.

AU - Stupp, Roger

PY - 2012/4

Y1 - 2012/4

KW - Recurrent glioblastoma

KW - End-points

KW - Overall survival

KW - Progression-free survival

KW - Overall survival rates

U2 - 10.1016/j.ejca.2011.10.027

DO - 10.1016/j.ejca.2011.10.027

M3 - Article

C2 - 22119352

VL - 48

SP - 896

EP - 903

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -